# Merck KGaA Agrees to Acquire Bio-Techne for $11.3 Billion in Largest Life Science Tools Deal of 2026

> ma · REPORTED · 2026-06-25

On June 25, 2026, Merck KGaA announced a definitive all-cash agreement to acquire Minneapolis-based Bio-Techne at $73 per share, representing an $11.3 billion enterprise value and a 36% premium, marking Merck's largest acquisition since Sigma-Aldrich in 2015 and combining Bio-Techne's portfolio of 425,000 antibodies, RNAscope spatial biology, and ProteinSimple protein analysis instruments with Merck's global life science infrastructure.

- Company: Merck KGaA / Bio-Techne
- Sector: diagnostics
- Primary source: https://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-agrees-to-acquire-bio-techne-strengthening-leadership-position-in-fast-growing-life-sciences-markets-302810602.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.